Seven compounds having varying affinities for peripheral benzodiazepine (p sites) were evaluated in vitro as inhibitors of arachidonic acid-induced rabbit platelet aggregation and thromboxane B2 (TXB2) synthesis. With the exception of flumazenil, all compounds inhibited both parameters with IC50 values ranging from 0.19 to 3.5 microM, with a significant correlation between the inhibition of aggregation and the synthesis of thromboxane B2. The antiaggregatory effect was stereoselective, and inhibition was increased when cellular penetration was favoured by increasing the volume of the organic solvent. The order of potency these compounds is consistent with an effect at intracellular p sites (Ro5-4864 > PK14067 > PK 11195 >> PK 14068 > or = clonazepam > or = diazepam >>> flumazenil). However, the correlation between the aggregation inhibition and the synthesis of TXB2 suggests that microsomal cyclooxygenase may be the intracellular target of these ligands. We therefore propose that this enzyme possesses a site for benzodiazepine ligands which may share certain characteristics with the peripheral benzodiazepine receptor.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0049-3848(95)00062-v | DOI Listing |
J Physiol
January 2025
Department of Biomedical Sciences, University of Padova, Padova, Italy.
The permeability transition (PT) is a permeability increase of the mitochondrial inner membrane causing mitochondrial swelling in response to matrix Ca. The PT is mediated by regulated channel(s), the PT pore(s) (PTP), which can be generated by at least two components, adenine nucleotide translocator (ANT) and ATP synthase. Whether these provide independent permeation pathways remains to be established.
View Article and Find Full Text PDFLancet Haematol
January 2025
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Background: Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of follicular lymphoma.
Methods: We did a single-arm, investigator-initiated, phase 2 trial at Sylvester Comprehensive Cancer Center in Miami, FL, USA.
Pharmacol Ther
February 2025
Department of Pharmacology, University of Belgrade - Faculty of Pharmacy, Belgrade 11000, Serbia. Electronic address:
The role of γ- aminobutyric acid (GABA) and GABA receptors is not only essential for neurotransmission in the central nervous system (CNS), but they are also involved in communication in various peripheral tissues such as the pancreas, liver, kidney, gastrointestinal tract, trachea, immune cells and blood vessels. GABA receptors located outside the CNS ("peripheral GABA receptors") enable both neuronal and non-neuronal GABA-ergic signaling in various physiological processes and are generally thought to have similar properties to the extrasynaptic receptors in the CNS. By activating these peripheral receptors, GABA and various GABA receptor modulators, including drugs such as benzodiazepines and general anesthetics, may contribute to or otherwise affect the maintenance of general body homeostasis.
View Article and Find Full Text PDFJ Anal Toxicol
November 2024
FT-LAB, Department of Health Science, University of Florence.
J Pain
November 2024
Department of Neuroscience and Center for Advanced Pain Studies, The University of Texas at Dallas, 860 N. Loop Rd., Richardson, TX 75080, USA. Electronic address:
Pain hyperacusis, also known as noxacusis, causes physical pain in response to sounds that do not bother most people. How sound causes excruciating pain that can last for weeks or months is not well understood, resulting in a lack of effective treatments. To gain insight into the underlying mechanisms of the condition, 32 adults attended a virtual focus group to describe their sound-induced pain.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!